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H
istory, to the Roman Cicero, is “the witness of
time, the life of memory, the mistress of life.”
But history can be a cruel mistress, illustrating
all we have not achieved. A glance back chal-
lenges us to reconsider what we have learned about type 1
diabetes and to what effect. More specifically, what hap-
pened after 1974, the annus mirabilis, when The Lancet
reported the genetic basis of this disease (through HLA
genes) (1) and a principle disease-associated biomarker
(islet cell autoantibodies) (2). Certainly, we can predict the
disease broadly based on these two observations, allied to
progressive loss of insulin secretion, but without any tan-
gible clinical benenfit. For the purpose of prediction is
prevention, and that, thus far, we cannot do. As a result,
attention has focused on nongenetic, specifically environ-
mental, factors that lead to type 1 diabetes and might be
modified. Two features of such environmental effects have
had an impact on our understanding of the disease path-
ogenesis, as illustrated in this month’s Diabetes (3). First,
early environmental events appear to cause type 1 diabetes
(4). Second, the age at diagnosis of this disease impacts the
clinical phenotype (5).
Twin, migration, population, and birth cohort studies
emphasize the importance of environmental factors oper-
ating in early childhood when disease-predictive autoanti-
bodies appear (6). Even disproportionate maternal and
birth-related events can influence the disease risk (Table 1).
Other putative factors include temperate climate, increased
hygiene, increasing wealth, overcrowding in childhood, vi-
rus infections, early diet including exposure to cow’s milk,
reduced rates or duration of breast feeding, and vitamin D
(4,5). Paradoxically, the most powerful evidence charac-
terizing such factors comes from genetic studies because
genetic associations unequivocally point toward predis-
position and cannot be an epiphenomenon. For example,
two genes—DHCR7 and CYP2R1—that are each directly
linked to vitamin D levels, are among three key genes as-
sociated with 25(OH) vitamin D metabolism and diabetes
susceptibility (7).
Virus infections have also been implicated, and entero-
virus infections presage the appearance of autoantibodies,
potentially contributing to rapid disease progression (8).
Cellular factors that mediate defense against viruses include
products of many interferon-stimulated genes, which en-
compass inhibitory activities (9). Of these genes, one cluster
containing the macrophage interferon regulatory factor
7–driven inflammatory network is enriched for diabetes-
associated genes and includes rare genetic variants of
IFIH1, a cytoplasmic helicase involved in protection from
viruses (10). Autoantibody-positive children, with an IFIH1
disease-protective genotype, progress less rapidly to di-
abetes than those with different genotypes (11).
Much of our current knowledge is based on this rela-
tively modest armamentarium of genetic analyses plus
autoantibodies. Therefore, any additional biomarker would
be enormously valuable. Metabolomics, the detection and
quantifiction of small molecules in a biological sample, has
the advantage of being unbiased and so hypothesis-free as
with genome-wide associated studies. It is also less com-
plex than genomic or proteomic analyses, given the num-
bers of human endogenous metabolites (several thousand)
compared with gene variants (multiple polymorphisms
of ;3 3 104 human genes) and proteins (;5 3 105 –106,
including splicing variants and posttranslational mod-
ifications). A remarkable study of 56 children who pro-
gressed to type 1 diabetes found that phosphatidylcholine
was reduced at birth, independent of HLA risk, with in-
creased levels of proinflammatory lysophosphatidylcho-
line several months before seroconversion to autoantibody
positivity, but not thereafter (12). Thus, early lipid dysreg-
ulation with increased oxidative stress may influence dis-
ease pathogenensis. Now the same metabolomic method
has been applied to the Munich birth cohort, which dem-
onstrates, after seroconversion, increased odd-chain
triglycerides and polyunsaturated fatty acid–containing
phospholipids in autoantibody-positive compared with
autoantibody-negative children, who are at high and low
risk, respectively, for diabetes (3). But children who de-
veloped autoantibodies by age 2 years also had persistent
twofold lower concentrations of methionine compared with
children who either developed autoantibodies later or were
autoantibody negative. By implication, pathways utilizing
methionine could be relevant to time to appearance of
autoantibodies and, by inference, clinical disease. Methio-
nine, like choline, is an epigenetic regulator, the former
TABLE 1
List of potential birth-related risk factors for type 1 diabetes
Born to diabetic fathers rather than diabetic mothers
Having a diabetic mother aged ,8 years at diagnosis compared
with a mother diagnosed later
Increasing maternal age at delivery
First born
ABO incompatibility with the mother
Season of delivery
More maternal enterovirus infections
Early cessation of breast feeding
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because it is a methyl-donor, important in transmethylation
and one-carbon moiety pathways. Methionine is, there-
fore, involved in DNA methylation, an epigenetic effect
putatively involved in autoimmunity (13). Moreover, an
imprinted gene, a quintessential epigenetic effect, has
been implicated in diabetes genetic susceptibility (14).
However, the low plasma methionine in the young high
disease-risk subset is not likely to cause diabetes, since it
is only found in very young autoantibody-positive chil-
dren, more likely reflecting a marker for rapid disease
progression.
These observations bring us back to the heterogeneity of
autoimmune diabetes according to age at diagnosis, which
is severe and insulin dependent in childhood but often
mild and noninsulin requiring in adulthood (15). That
heterogeneity highlights the differential character of the
disease process beyond clinical differences. Thus, chil-
dren at diagnosis compared with adults have higher HLA
genetic risk, more antigen-specific autoantibodies, and
greater insulin deficiency (15). Genetic risk aside, such
heterogeneity could result from similar environmental
events operating at disparate times, different factors op-
erating at the same time, or both. Evidence supports the
latter (Fig. 1). Age at diagnosis is strongly correlated with
age of appearance of the first autoantibody; when auto-
antibodies appear before age 5 years, they tend to be mul-
tiple, antigen-specific, isotype restricted, high titer, and
highly predictive of disease (4). Autoantibodies appearing
after age 8 years are often directed against single antigens,
at low titer, with reduced predictive value (4). If, as seems
likely, autoantibodies reflect disease-associated environ-
mental events, then the timing of that critical exposure
impacts clinical outcome. Such distinctions are now shown
to encompass metabolic changes, including low plasma
methionine, with the caveat that metabolomics, like auto-
antibodies, may be an epiphenomenon. As when immuno-
genetic changes were initially identified, future developments
will be methodological and descriptive—the former through
improved assays and sample collection, the latter by
exploiting cohort studies, other diseases, and animal
models to define the robustness, specificity, and causa-
tion of the results (16).
Autoimmune diabetes has a broad clinical spectrum
according to age at diagnosis. That spectrum is now shown
to result from differential immunogenetic and nongenetic
effects, including metabolic effects, in the prediabetic pe-
riod, and these effects influence the likelihood and rate
of disease progression (4,5,17–20) (Fig. 1). We have been
the witness of time, and time in science offers hope. For
with the most modest of tools and with time, we have
transformed our understanding of this disease. The ad-
dition of the metabolome as a further biomarker prom-
ises a rich harvest.
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